Follicular lymphoma trials in United States

In United States 102 Also abroad 189

102 trials · From ClinicalTrials.gov, checked 14 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Where
Anchorage, Arlington Heights, Austin, Baltimore, Birmingham, Boston, Duarte, Fairfax, Fort Worth, Fredericksburg, Hattiesburg, Iowa City, Jacksonville, Lexington, Little Rock, Marietta, Mobile, Newnan, Providence, Roanoke, San Antonio, San Francisco, Tampa, Towson, Tyler, Vancouver, Waukee, Westwood
Age
18 years and over
People
400 worldwide
Run by
Celgene
See details and how to joinNCT06911502 · EU 2024-519152-82-00
Phase 1Taking people
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Where
Duarte
Age
18 years and over
People
37
Run by
City of Hope Medical Center
See details and how to joinNCT06859008
Phase 1/2Taking people
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Where
Canton, Chicago, Dallas, Duarte, Los Angeles, Louisville, Memphis, Omaha, Weeki Wachee, Whittier
Age
12 years to 95 years
People
144
Run by
AVM Biotechnology Inc
See details and how to joinNCT04329728
Phase 1/2Taking people
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Where
Valhalla
Age
12 years to 70 years
People
20
Run by
New York Medical College
See details and how to joinNCT04491370
Phase 1Taking people
SynKIR-310 for Relapsed/Refractory B-NHL
Where
Atlanta, Denver, Fairway, New Brunswick, Philadelphia
Age
18 years and over
People
36
Run by
Verismo Therapeutics
See details and how to joinNCT06544265
Phase 2Taking people
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
Where
Ann Arbor, Fort Myers, Miami, New Brunswick, Pittsburgh
Age
18 years and over
People
100
Run by
Juan P. Alderuccio, MD
See details and how to joinNCT04998669
Phase 1Taking people
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Where
Bethesda, Chicago, Cincinnati, Columbus, Dallas, Denver, Duarte, Houston, Miami Beach, Nashville, New York, Orange, Salt Lake City, San Francisco, Sarasota, Seattle
Age
18 years and over
People
248
Run by
Nurix Therapeutics, Inc.
See details and how to joinNCT04830137
Phase 2Taking people
Odronextamab in Low Tumor Volume Advanced FL
Where
Boston
Age
18 years and over
People
35
Run by
Gottfried von Keudell, MD PhD
See details and how to joinNCT07128641
Phase 2Taking people
Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells
Where
Duarte
Age
18 years and over
People
56
Run by
City of Hope Medical Center
See details and how to joinNCT07042438
Phase 1Taking people
CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
Where
Columbus
Age
18 years and over
People
18
Run by
Nathan Denlinger
See details and how to joinNCT06209619
Phase 1/2Taking people
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Where
Milwaukee
Age
18 years to 80 years
People
100
Run by
Medical College of Wisconsin
See details and how to joinNCT04186520
Phase 1Taking people
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Where
Cincinnati, Columbus, Durham, Salt Lake City
Age
18 years and over
People
60
Run by
Newave Pharmaceutical Inc
See details and how to joinNCT04775745
Phase 1Taking people
Study of SGR-1505 in Mature B-Cell Neoplasms
Where
Boston, Buffalo, Canton, Columbus, Dallas, Durham, Gilbert, Hackensack, Milwaukee, Newark, New York, Pompano Beach, Portland, Providence, Seattle, The Bronx
Age
18 years and over
People
98 worldwide
Run by
Schrödinger, Inc.
See details and how to joinNCT05544019 · EU 2023-505204-34-00
Phase 1Taking people
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Where
Jacksonville
Age
18 years and over
People
27
Run by
Mayo Clinic
See details and how to joinNCT06191887
Phase 2Taking people
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Where
Atlanta
Age
18 years and over
People
49
Run by
Emory University
See details and how to joinNCT04883437
Phase 1/2Taking people
Evaluate the Safety and Clinical Activity of HH2853
Where
Jacksonville, Phoenix, Rochester, San Antonio
Age
18 years and over
People
254 worldwide
Run by
Haihe Biopharma Co., Ltd.
See details and how to joinNCT04390737
Phase 1Taking people
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Where
Chapel Hill
Age
18 years and over
People
20
Run by
UNC Lineberger Comprehensive Cancer Center
See details and how to joinNCT04223765
Phase 1Taking people
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
Where
Canton, Columbus, Dallas, Fairfax, Houston, Los Angeles, Pittsburgh, Tamarac
Age
18 years and over
People
168 worldwide
Run by
OncoNano Medicine, Inc.
See details and how to joinNCT06022029
Phase 1Taking people
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Where
Baltimore, Chicago, Durham, Fort Wayne, Houston, Maumee, Miami Beach, Milwaukee, Orange, Tampa, Westbury, Worcester
Age
18 years and over
People
120
Run by
Carna Biosciences, Inc.
See details and how to joinNCT05602363
Phase 1/2Taking people
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Where
Salt Lake City, San Antonio, St Louis, Westwood
Age
18 years and over
People
120 worldwide
Run by
CRISPR Therapeutics AG
See details and how to joinNCT05643742
No phaseTaking people
Long-term Follow-up Study of Patients Receiving CAR-T Cells
Where
Milwaukee
Age
18 years to 80 years
People
500
Run by
Medical College of Wisconsin
See details and how to joinNCT03375619
No phaseTaking people
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Where
Albuquerque, Ann Arbor, Atlanta, Aurora, Baltimore, Bethesda, Billings, Birmingham, Boise, Buffalo, Chapel Hill, Charlottesville, Chicago, Cincinnati, Columbus, Dallas, Denver, Duarte, Duluth, Fargo, Greenville, Hartford, Hattiesburg, Hempstead, Houston, Iowa City, Irvine, Jacksonville, Kansas City, La Jolla, Lansing, Little Rock, Littleton, Manhasset, Mayfield Heights, Memphis, Miami, Milwaukee, Mobile, Morgantown, Nashville, Newark, New Brunswick, New Orleans, New York, Norwalk, Omaha, Orange, Philadelphia, Portland, Providence, Salt Lake City, San Francisco, Savannah, Scarborough, Scottsdale, Seattle, Silver Spring, Stanford, Staten Island, St Louis, Tampa, Temple, Towson, Tulsa, Winston-Salem, Worcester
People
50,000 worldwide
Run by
Massive Bio, Inc.
See details and how to joinNCT03452774
Phase 1Taking people
Q702 for the Treatment of Patients With Hematologic Malignancies
Where
Rochester, Scottsdale
Age
18 years and over
People
46
Run by
Mayo Clinic
See details and how to joinNCT06712810
Phase 1Taking people
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Where
Chapel Hill, Cleveland, Columbus, Dallas, Denver, Nashville, Portland, Sarasota, Seattle
Age
18 years and over
People
60
Run by
Accutar Biotechnology Inc
See details and how to joinNCT05780034
No phaseTaking people
A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting
Where
Milwaukee
Age
18 years and over
People
300
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06794268